Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period-Reference-Cited by-同舟云学术

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

Published:2013-07-31 Issue:12 Volume:27 Page:1899-1909
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Kyeyune Fred,Nankya Immaculate,Metha Samar,Akao Juliet,Ndashimye Emmanuel,Tebit Denis M.,Rodriguez Benigno,Kityo Cissy,Salata Robert A.,Mugyenyi Peter,Arts Eric J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference41 articles.

1. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study.;Mermin;Lancet,2008

2. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.;Campbell;PLoS Med,2012

3. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana.;Ojikutu;Curr Infect Dis Rep,2008

4. Overcoming challenges to the implementation of antiretroviral therapy in Kenya.;Taegtmeyer;Lancet Infect Dis,2002

5. Should the CD4 threshold for starting ART be raised.;Wood;Lancet,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Per-pathogen virulence of HIV-1 subtypes A, C and D;Proceedings of the Royal Society B: Biological Sciences;2023-05-10

2. We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy;The Lancet HIV;2023-03

3. In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs;International Journal of Molecular Sciences;2022-12-06

4. In vitro susceptibility of HIV isolates with high growth capability to antiretroviral drugs;2022-10-20

5. In vitro antiviral activity of currently available drugs against primary HIV isolates with high growth capability;2022-08-29